GeoVax Labs announced the publication of a new scientific paper detailing the latest on the company’s efforts against Zika.
GeoVax Labs (OTCQB:GOVX) announced the publication of a new scientific paper detailing the latest on the company’s efforts against Zika.
As quoted in the press release:
The paper published today reports research showing that a single intramuscular dose of GeoVax’s Zika vaccine (GEO-ZM02) provided 100% protection in normal mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is i) the only Zika vaccine in development which is based solely on the ZIKV NS1 protein, and ii) the first report of single-dose vaccine that afforded full protection against ZIKV using an immunocompetent lethal mouse challenge model.
The vaccine was tested at the Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC) in Fort Collins, Colorado with funding from the CDC. In the study, outbred immunocompetent mice were exposed to a lethal challenge dose of ZIKV delivered directly into the brain. A single dose of GeoVax’s ZIKV NS1 vaccine protected 100% of vaccinated animals. In contrast, 80-90% of sham-immunized control animals died within ~7 days.